Cargando…
Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
The impact of secondary infections (SI) on COVID‐19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients...
Ejemplares similares
-
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
por: Passamonti, Francesco, et al.
Publicado: (2020) -
COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
por: Passamonti, Francesco, et al.
Publicado: (2021) -
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
por: Visco, Carlo, et al.
Publicado: (2022) -
Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
por: Giannini, Edoardo G., et al.
Publicado: (2019) -
Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial
por: Bruna, Riccardo, et al.
Publicado: (2019)